30 Day Trial

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Year in Review

2014 Revenue: Exactech

4Q14 revenue: $63.3MM, +4% (U.S. $41.7MM, flat; ex-U.S. $21.6MM, +9%)

  • Hips $11.3, +12%
  • Knees $18.9MM, -7%
  • Biologic & Spine $6.1MM, -8%
  • Extremity $21.7MM, +18%
  • Other $5.2MM, -13%


2014 revenue: of $248.1MM, +5% (U.S. $165.6MM, +4%, ex-U.S. $82.8MM, +7%

  • Hips $43.5MM, +6%
  • Knees $78.7MM, -2%
  • Biologic & Spine $23.8MM, -7%
  • Extremity $79.0MM, +21%
  • Other $23.4MM, -5%


  • Shoulders still led by growth in Equinoxe®
  • Hips buoyed by introduction of Alteon®, featuring a tapered wedge Femoral Stem and Neck Preserving Femoral Stem
  • Equinoxe GPS scheduled for early 2016
  • Knee unit sales up worldwide, but faced pricing pressure
  • Currency specifically impacted knee sales (the largest volume of product sold ex-U.S.)
  • Expecting knees to be affected in 2H15 by new product launches (GPS system V2), product development, etc.
  • Updated revision knee (Logic CC) to commence surgery this summer
  • RBK knee product not expected to receive FDA clearance until 2016
  • Starting to launch CTA humeral heads and resurfacing product ex-U.S. in 1Q
  • Hip, knee and shoulder education programs “basically overregistered”
  • Acquisition of Blue Ortho may benefit not only knee but shoulder replacement, as well
  • Planning 3Q15 1st cases with ankle product, assuming FDA clearance, with possible launch in 1H16
  • 2Q launches include Ambassador cervical plate, Ascendant cervical interbody device